1 - 3 June, 2027
Congress CenterBasel Switzerland Niccolo Pengo, PhDChief Scientific Officer at Mabylon AGSpeaker
Profile
Niccolo Pengo, after obtaining a PhD at San Raffaele University in Milan on B-cell immunology and investigating regulation of cellular degradative pathways at University College London (Pengo et al. Nat Immunol 2013, Pengo et al. Nat Comm 2017), continued his research in industry working on developing novel antibody therapeutics, first at UCB pharma in the UK, and then as Chief Scientific Officer of Mabylon, in Switzerland, a company dedicated to the discovery of novel human derived antibody therapeutics in immunology and neurodegeneration.
Agenda Sessions
Next-Generation Allergy Therapy: Engineering Patient Antibodies into Long-Acting Neutralizing Multispecifics
, 16:25View Session